Aligos Therapeutics Inc

ALGS

Company Profile

  • Business description

    Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

  • Contact

    One Corporate Drive
    2nd Floor
    South San FranciscoCA94080
    USA

    T: +1 800 466-6059

    E: [email protected]

    https://www.aligos.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    70

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,815.305.00-0.06%
CAC 407,829.2972.96-0.92%
DAX 4024,255.31201.50-0.82%
Dow JONES (US)44,371.51279.13-0.63%
FTSE 1008,941.1234.54-0.38%
HKSE24,239.4799.900.41%
NASDAQ20,585.5345.14-0.22%
Nikkei 22539,459.62110.06-0.28%
NZX 50 Index12,678.697.99-0.06%
S&P 5006,259.7520.71-0.33%
S&P/ASX 2008,570.409.70-0.11%
SSE Composite Index3,528.6718.490.53%

Market Movers